2024
INTERACTIONS BETWEEN MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 MEDIATES PULMONARY FIBROSIS
LEE C, TRUJILLO G, REGUEIRO-REN A, LIU C, HU B, SUN Y, KHOURY J, KHOURY J, AHANGARI F, ISHIKAWA G, WALIA A, PIVARNIK T, YU S, WOO S, FIORINI V, MCGOVERN J, AL JUMAILY K, SUN H, PENG X, ANTIN-OZERKIS D, SAULER M, KAMINSKI N, HERZOG E. INTERACTIONS BETWEEN MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 MEDIATES PULMONARY FIBROSIS. CHEST Journal 2024, 166: a3384-a3386. DOI: 10.1016/j.chest.2024.06.2020.Peer-Reviewed Original ResearchToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024 PMID: 39189851, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelBexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster L, Cottin V, Ramaswamy M, Wuyts W, Jenkins R, Scholand M, Kreuter M, Valenzuela C, Ryerson C, Goldin J, Kim G, Jurek M, Decaris M, Clark A, Turner S, Barnes C, Achneck H, Cosgrove G, Lefebvre É, Flaherty K, Baratz D, Ettinger N, Layish D, Epstein M, Veeraraghavan S, Golden J, Ramaswamy M, Bascom R, Lancaster L, Scholand M, Case A, Zaman T, Betensley A, Antin-Ozerkis D, Montessi S, Fernandez E, Boente R, Sager J, Hunninghake G, Gibson K, Srour N, Dhar A, Wuyts W, Wielders P, Veltkamp M, Mostard R, Janssen R, Noordegraaf A, Glaspole I, Corte T, Beckert L, Brockway B, Veale A, Richeldi L, Harari S. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. American Journal Of Respiratory And Critical Care Medicine 2024, 210: 424-434. PMID: 38843105, PMCID: PMC11351797, DOI: 10.1164/rccm.202403-0636oc.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsQuantitative lung fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisRates of treatment-emergent adverse eventsIncidence of treatment-emergent adverse eventsClinical trialsTreatment of idiopathic pulmonary fibrosisExploratory efficacy endpointsImpaired quality of lifeFibrosis-related biomarkersDose cohortsBackground therapyPlacebo groupTolerability profileOnce-dailyEfficacy endpointPrimary endpointProgressive diseaseExertional dyspneaFVC declineFibrosis biomarkersAdverse eventsIPF therapyLung fibrosisPamrevlumab for Idiopathic Pulmonary Fibrosis
Raghu G, Richeldi L, Fernández Pérez E, De Salvo M, Silva R, Song J, Ogura T, Xu Z, Belloli E, Zhang X, Seid L, Poole L, Bowler S, Corte T, Holmes M, Thien F, Wheatley J, Choi S, Chung M, Jeong S, Kim Y, Lee E, Lee H, Park C, Park J, Park J, Chi-Leung Lam D, Chan M, Lee K, Cao J, Chen J, Chen R, Dai H, Fu X, Liang Z, Luo Q, Shi G, Tong Z, Wang L, Yang S, Yu H, Zhang H, Zhang J, Zhao H, Wang W, Meng Y, Peng H, Ramaswamy M, Hamblin M, Fitzgerald J, Gupta N, Dematte J, Veeraraghavan S, O’Brien T, Luckhardt T, Lancaster L, Kokoszynska M, Ettinger N, Kaelin T, Siddiqi A, Collins B, Scholand M, Antin-Ozerkis D, Hyun K, Harden C, Averill F, Mallea J, Bascom R, Seeram V, Hajari Case A, Britt E, Shea B, Criner G, Gotfried M, Mageto Y, El Bayadi S, Reichner C, Mooney J, Hotchkin D, Abrencillo R, Boente R, Lee J, Betensley A, Jeganathan N, Walia R, Albertson T, Rosas I, Puppala D, Abraham L, Enelow R, Bhatt N, Bandyopadhyay D, Elias P, Bergna M, Garcia G, De Stefano G, Wehbe L, Chirino A, Rojas R, Otaola M, Miranda G, Florenzano M, Silva Orellana R, Glasinovich V, Shangina O, Nikishenkov A, Kuzubova N. Pamrevlumab for Idiopathic Pulmonary Fibrosis. JAMA 2024, 332: 380-389. PMID: 38762797, PMCID: PMC11304118, DOI: 10.1001/jama.2024.8693.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisBaseline to weekPulmonary fibrosisAdverse eventsBetween-group differencesPrimary outcomePhase 3 randomized clinical trialSecondary outcomesTreatment-related adverse eventsProgression of idiopathic pulmonary fibrosisPhase 2 trialAssociated with adverse eventsRate of lung function declineSubstantial adverse eventsAbsolute changeStatistically significant between-group differencesPatient-reported symptomsLung function declineSignificant between-group differencesFollow-up encountersPatient-reported outcomesPlacebo groupAntifibrotic treatmentPamrevlumabClinical trials2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1051-1069. PMID: 38973731, DOI: 10.1002/acr.25348.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1070-1082. PMID: 38973729, DOI: 10.1002/acr.25347.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1201-1213. PMID: 38973714, DOI: 10.1002/art.42860.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1182-1200. PMID: 38978310, DOI: 10.1002/art.42861.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendationsEvaluation of the Contribution of Clinical Parameters for the Diagnosis of Idiopathic Pulmonary Fibrosis by an International Panel of Clinicians
Abecassis C, Pastre J, Hajari Case A, Antin-Ozerkis D, Shifren A, Libre E, Picone C, Johri S, Hindre R, Benattia A, Riviere F, Wemeau L, Ouaknine J, Taverne J, Hamdan A, Ben Dhiab R, Chung J, Dubocage A, Maillard A, King C, Nathan S. Evaluation of the Contribution of Clinical Parameters for the Diagnosis of Idiopathic Pulmonary Fibrosis by an International Panel of Clinicians. 2024, a1766-a1766. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1766.Peer-Reviewed Original ResearchContinued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON
Bonella F, Wuyts W, Chaudhuri N, Varone F, Antin-Ozerkis D, Song J, Miede C, Dumistracel M, Coeck C, Cottin V. Continued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON. Pneumologie 2024, 78: s79-s79. DOI: 10.1055/s-0044-1781400.Peer-Reviewed Original Research
2023
Continued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON
Wuyts W, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Song J, Miede C, Dumistracel M, Coeck C, Cottin V. Continued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON. 2023, pa2874. DOI: 10.1183/13993003.congress-2023.pa2874.Peer-Reviewed Original ResearchEffects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold A, Kuwana M, Merkel P, Stock C, Sambevski S, Denton C, Bergna M, Casado G, Walter P, Proudman S, Stevens W, Thakkar V, Troy L, Loeffler-Ragg J, Olschewski H, André B, Bondue B, Houssiau F, Smith V, Wuyts W, Azevedo V, Johnson S, Keystone E, Khalidi N, Levesque M, Rozas R, Orellana A, Huang C, Li J, Jiang Z, Liu Y, Xiao W, Xu J, Zeng X, Zheng Y, Zou H, Becvar R, Madsen H, Søndergaard K, Kilpeläinen M, Myllärniemi M, Agard C, Allanore Y, Bourdin A, Cottin V, Crestani B, Diot E, Dominique S, Hachulla E, Jouneau S, Leroy S, Nunes H, Prevot G, Wallaert B, Wemeau L, Aringer M, Bewig B, Blaas S, Distler J, Ehrchen J, Ewert R, Gläser S, Henes J, Hunzelmann N, König R, Kötter I, Kreuter M, Prasse A, Schulze-Koops H, Sfikakis P, Vlachoyiannopoulos P, Losonczy G, Behera D, Devi H, Kadel J, Kawedia M, Kumar D, Kumar U, Lokhande R, Malpani A, Mohan M, Nalawade A, Parakh U, Swarnakar R, Shobha V, Thangakunam B, Udwadia Z, Henry M, O'Reilly K, Balbir-Gurman A, Kramer M, Litinsky I, Rosner I, Cutolo M, Gabrielli A, Iaccarino L, Pesci A, Riccieri V, Vettori S, Funakubo Y, Inoue Y, Kawakami A, Kawaguchi Y, Kawamura T, Kondoh Y, Kuwana M, Nanki T, Nishioka Y, Nozawa K, Ogura T, Okamoto M, Sano H, Sasai R, Sasaki N, Suda T, Takahashi H, Takeuchi T, Makino S, Tanaka S, Yamasaki Y, Ch'ng S, Cheah C, Kan S, Mohamed R, Selman M, de Vries-Bouwstra J, van den Toorn L, Vonk M, Voskuyl A, Hoffmann-Vold A, Seip M, Dankiewicz-Fares I, Olesiejuk R, Pulka G, Szepietowski J, Alves J, Bernardes M, Cordeiro A, Costa J, Neves S, Salvador M, Sancho J, Delgado P, Barranco I, Martínez J, del Castillo A, Ovalles J, López-Longo F, Gallego A, Dapena M, Ivorra J, Ekwall A, Maurer B, Mihai C, Müller R, Mahakkanukrauh A, Nantiruj K, Siripaitoon B, Denton C, Herrick A, Madhok R, Maher T, West A, Antin-Ozerkis D, Bascom R, Criner G, Csuka M, D'Amico J, Ettinger N, Fischer A, Gerbino A, Gerke A, Glassberg M, Glazer C, Golden J, Gripaldo R, Gupta N, Hamblin M, Highland K, Ho L, Huggins J, Hummers L, Jones L, Kahaleh M, Khanna D, Kim H, Lancaster L, Luckhardt T, Mayes M, Ballesteros F, Mooney J, Mohabir P, Morrissey B, Moua T, Padilla M, Patel N, Perez R, Roman J, Rossman M, Russell T, Saketkoo L, Shah A, Shlobin O, Scholand M, Simms R, Spiera R, Steen V, Veeraraghavan S, Weigt S. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology 2023, 63: 639-647. PMID: 37294870, PMCID: PMC10907814, DOI: 10.1093/rheumatology/kead280.Peer-Reviewed Original ResearchLimited cutaneous systemic sclerosisInterstitial lung diseaseCutaneous systemic sclerosisSENSCIS trialEffect of nintedanibWeek 52Nintedanib groupPlacebo groupSystemic sclerosisLung diseaseProgressive fibrosing interstitial lung diseasesOpen-label nintedanibSSc-ILDLung functionPulmonary fibrosisNintedanibPatientsRate of declineFVCTrialsPlaceboSclerosisDiseaseGroupFibrosisZiritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
Maher T, Ford P, Brown K, Costabel U, Cottin V, Danoff S, Groenveld I, Helmer E, Jenkins R, Milner J, Molenberghs G, Penninckx B, Randall M, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins T, Wuyts W, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek M, Chambers D, Chia M, Corte T, Glaspole I, Goh N, Holmes M, Malouf M, Thien F, Veitch E, Bondue B, Dahlqvist C, Froidure A, Slabbynck H, Wuyts W, Cartagena Salinas C, Feijoó Seoane R, Martínez V, Maturana R, Pavie Gallegos J, Rosenblut A, Silva R, Undurraga Pereira A, Doubkova M, Pauk N, Plackova M, Sterclova M, Bendstrup E, Shaker S, Titlestad I, Budweiser S, Grohé C, Koschel D, Kreuter M, Prasse A, Weber M, Wirtz H, Antoniou K, Daniil Z, Gaga M, Papakosta D, Izumi S, Okamoto M, Guerreros Benavides A, Iberico Barrera C, Peña Villalobos A, Campo Ezquibela A, Cifrian Martinez J, Fernandez Fabrellas E, Leiro V, Molina-Molina M, Nieto Barbero A, Sellares Torres J, Valenzuela C, Cheng S, Kuo P, Lee K, Sheu C, Gunen H, Mogulkoc Bishop N, Nayci S, Adamali H, Bianchi S, Chaudhuri N, Gibbons M, Hart S, Molyneaux P, Parfrey H, Saini G, Spencer L, Wiscombe S, Antin-Ozerkis D, Bascom R, Belperio J, Britt E, Fitzgerald J, Gomez Manjarres D, Gotfried M, Gupta N, Hotchkin D, Kaye M, Kreider M, Kureishy S, Lacamera P, Lancaster L, Lasky J, Lorch D, Mannem H, Morrow L, Moua T, Nambiar A, Raghu G, Raj R, Ramaswamy M, Reddy R, Russell T, Scholand M, Shea B, Suliman S, Swigris J, Thavarajah K, Tolle L, Tomic R, Warshoff N, Wesselius L, Yung G, Bergna M, De Salvo M, Fernandez Acquier M, Rodriguez A, Saez Scherbovsky P, Assayag D, Dhar A, Khalil N, Morisset J, Provencher S, Ryerson C, Shapera S, Bourdin A, Crestani B, Lebargy F, Reynaud-Gaubert M, Bonella F, Claussen M, Hammerl P, Karagiannidis C, Keller C, Randerath W, Stubbe B, Csánky E, Medgyasszay B, Muller V, Adir Y, Bar-Shai A, Berkman N, Fink G, Kramer M, Shitrit D, Bargagli E, Gasparini S, Harari S, Ravaglia C, Richeldi L, Vancheri C, Ebina M, Fujita M, Ichikado K, Inoue Y, Ishikawa N, Kato M, Kawamura T, Kondoh Y, Nishioka Y, Ogura T, Owan I, Saito T, Sakamoto N, Sakamoto K, Shirai M, Suda T, Tomii K, Chung M, Jeong S, Park C, Park J, Song J, Uh S, Chavarria Martinez U, Montano Gonzalez E, Ramirez A, Selman Lama M, Bresser P, Kramer H, Mostard R, Nossent E, Veltkamp M, Wijsenbeek M, Beckert L, Chang C, Veale A, Wilsher M, Bednarek M, Gasior G, Jasieniak-Pinis G, Jassem E, Mroz R, Piotrowski W, Abdullah I, Ambaram A, Irusen E, Van der Linden M, van Zyl-Smit R, Williams P, Allen J, Averill F, Belloli E, Brown A, Case A, Chaudhary S, Criner G, DeBoer K, Dilling D, Dorf J, Enelow R, Ettinger N, Feldman J, Gibson K, Golden J, Hamblin M, Hunninghake G, Karunakara R, Kim H, Luckhardt T, Menon P, Morrison L, Oldham J, Patel N, Schmidt S, Strek M, Summer R, Sussman R, Tita J, Veeraraghavan S, Whelan T, Zibrak J. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis. JAMA 2023, 329: 1567-1578. PMID: 37159034, PMCID: PMC10170340, DOI: 10.1001/jama.2023.5355.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedClinical Trials, Phase III as TopicFemaleHumansIdiopathic Pulmonary FibrosisLungMaleMiddle AgedMulticenter Studies as TopicPhosphodiesterase InhibitorsQuality of LifeRandomized Controlled Trials as TopicRespiratory Physiological PhenomenaRespiratory System AgentsTreatment OutcomeConceptsIdiopathic pulmonary fibrosisKey secondary outcomesFVC declineSecondary outcomesPulmonary fibrosisCare treatmentSt George's Respiratory Questionnaire (SGRQ) total scoreRespiratory-related hospitalizationsSafety Monitoring CommitteeQuestionnaire total scoreNovel autotaxin inhibitorAnnual rateCause mortalityWeek 52Lung functionPrimary outcomeClinical outcomesVital capacityStudy terminationClinical trialsDisease progressionPlaceboMAIN OUTCOMEPatientsAutotaxin inhibitors
2022
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
Wuyts W, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Mueller H, Coeck C, Rohr K, Cottin V. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. 2022, 604. DOI: 10.1183/13993003.congress-2022.604.Peer-Reviewed Original ResearchLong-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study
Raghu G, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Burgess T, Kamath N, Donaldson F, Richeldi L. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research 2022, 23: 129. PMID: 35597980, PMCID: PMC9123757, DOI: 10.1186/s12931-022-02047-0.Peer-Reviewed Original ResearchConceptsOpen-label extensionIdiopathic pulmonary fibrosisWeek 128PRM-151Serious TEAEsPulmonary fibrosisPentraxin 2Efficacy dataRandomized periodTreatment-emergent adverse event profilesOpen-label extension studyAcute respiratory failureAdverse event profileNew safety signalsPatient-reported outcomesLimited efficacy dataLong-term safetyEudraCT 2014Lung transplantationRespiratory failureWalk distanceLong-term evaluationEvent profileVital capacityIntravenous infusionContinued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON*
Bonella F, Wuyts W, Chaudhuri N, Varone F, Antin-Ozerkis D, Mueller H, Coeck C, Rohr K, Cottin V. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON*. Pneumologie 2022, 76: s25-s26. DOI: 10.1055/s-0042-1747743.Peer-Reviewed Original Research
2021
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
Wuyts W, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Mueller H, Coeck C, Rohr K, Cottin V. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. 2021, pa2538. DOI: 10.1183/13993003.congress-2021.pa2538.Peer-Reviewed Original ResearchAn 84-Year-Old Physician With Progressive Dyspnea and Bilateral Upper Lobe Opacities
Harris ZM, Antin-Ozerkis D. An 84-Year-Old Physician With Progressive Dyspnea and Bilateral Upper Lobe Opacities. CHEST Journal 2021, 159: e325-e329. PMID: 33965157, DOI: 10.1016/j.chest.2020.12.035.Peer-Reviewed Original ResearchConceptsProgressive exertional dyspneaNumbness/tinglingLong-term medicationProximal muscle weaknessParoxysmal atrial fibrillationLifelong nonsmokersNaproxen 250Progressive dyspneaDry coughExertional dyspneaNight sweatsPulmonary clinicLumbar radiculopathySinus congestionSpinal stenosisAtrial fibrillationMuscle weaknessHashimoto's thyroiditisRecent travelMedical historyOlder physiciansWeight lossDyspneaThyroiditisPhysicians
2020
A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future
Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE, Chupp G, Cohn L, Dela Cruz CS, Ferrante LE, Herzog EL, Koff J, Rochester CL, Ryu C, Singh I, Tickoo M, Winks V, Gulati M, Possick JD. A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future. CHEST Journal 2020, 159: 949-958. PMID: 33159907, PMCID: PMC7641526, DOI: 10.1016/j.chest.2020.10.067.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute diseaseRespiratory syndromeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Post-intensive care syndromePotential long-term complicationsCOVID-19Respiratory syndrome coronavirus 2Middle East respiratory syndromeSevere acute respiratory syndromeCoronavirus disease 2019 (COVID-19) casesPersistent respiratory symptomsLong-term complicationsCOVID-19 survivorsSyndrome coronavirus 2Acute respiratory syndromeCOVID-19 outcomesChronic complicationsPersistent symptomsRespiratory symptomsCoronavirus 2Lung diseaseNonhospitalized individualsClinical programsComplicationsNintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Wells A, Flaherty K, Brown K, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts W, Stowasser S, Quaresma M, Goeldner R, Schlenker-Herceg R, Kolb M, investigators I, Abe S, Aburto M, Acosta O, Andrews C, Antin-Ozerkis D, Arce G, Arias M, Avdeev S, Barczyk A, Bascom R, Bazdyrev E, Beirne P, Belloli E, Bergna M, Bergot E, Bhatt N, Blaas S, Bondue B, Bonella F, Britt E, Buch K, Burk J, Cai H, Cantin A, Villegas D, Cazaux A, Cerri S, Chaaban S, Chaudhuri N, Cottin V, Crestani B, Criner G, Dahlqvist C, Danoff S, D'Amico J, Dilling D, Elias P, Ettinger N, Falk J, Pérez E, Gamez-Dubuis A, Giessel G, Gifford A, Glassberg M, Glazer C, Golden J, Carrera L, Guiot J, Hallowell R, Hayashi H, Hetzel J, Hirani N, Homik L, Hope-Gill B, Hotchkin D, Ichikado K, Ilkovich M, Inoue Y, Izumi S, Jassem E, Jones L, Jouneau S, Kaner R, Kang J, Kawamura T, Kessler R, Kim Y, Kishi K, Kitamura H, Kolb M, Kondoh Y, Kono C, Koschel D, Kreuter M, Kulkarni T, Kus J, Lebargy F, Jiménez A, Luo Q, Mageto Y, Maher T, Makino S, Marchand-Adam S, Marquette C, Martinez R, Martínez M, Rozas R, Miyazaki Y, Moiseev S, Molina-Molina M, Morrison L, Morrow L, Moua T, Nambiar A, Nishioka Y, Nunes H, Okamoto M, Oldham J, Otaola M, Padilla M, Park J, Patel N, Pesci A, Piotrowski W, Pitts L, Poonyagariyagorn H, Prasse A, Quadrelli S, Randerath W, Refini R, Reynaud-Gaubert M, Riviere F, Portal J, Rosas I, Rossman M, Safdar Z, Saito T, Sakamoto N, Fénero M, Sauleda J, Schmidt S, Scholand M, Schwartz M, Shapera S, Shlobin O, Sigal B, Orellana A, Skowasch D, Song J, Stieglitz S, Stone H, Strek M, Suda T, Sugiura H, Takahashi H, Takaya H, Takeuchi T, Thavarajah K, Tolle L, Tomassetti S, Tomii K, Valenzuela C, Vancheri C, Varone F, Veeraraghavan S, Villar A, Weigt S, Wemeau L, Wuyts W, Xu Z, Yakusevich V, Yamada Y, Yamauchi H, Ziora D. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine 2020, 8: 453-460. PMID: 32145830, DOI: 10.1016/s2213-2600(20)30036-9.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseIdiopathic pulmonary fibrosisIdiopathic non-specific interstitial pneumoniaAutoimmune interstitial lung diseaseUnclassifiable idiopathic interstitial pneumoniaNon-specific interstitial pneumoniaDose of nintedanibParallel-group trialIdiopathic interstitial pneumoniaEffect of nintedanibINBUILD trialInterstitial pneumoniaILD diagnosisHigh-resolution CTILD progressionFVC declineHypersensitivity pneumonitisProgressive fibrosing interstitial lung diseasesOverall populationInterstitial lung disease diagnosisChest imaging featuresProtocol-defined criteriaSafety of nintedanibChronic hypersensitivity pneumonitisDisease subgroup analyses